Autoantibodies to Abl and Bcr proteins. Leukemia 2000 Sep;14(9):1661-6
Date
09/20/2000Pubmed ID
10995014DOI
10.1038/sj.leu.2401870Scopus ID
2-s2.0-0033835428 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Formation of an aberrant, chimeric Bcr-Abl protein is the hallmark of Philadelphia (Ph) chromosome-positive leukemias. The Bcr-Abl protein, as well as its normal cellular counterparts--Abl and Bcr--are intracellular molecules with postulated roles in a variety of critical biologic functions. In this study, we demonstrate the existence of autoantibodies against these proteins. Plasma from 18 of 31 individuals (58%), including 14 of 20 Ph-positive CML patients (70%), two of four normal volunteers (50%), and two of seven patients with Ph-negative leukemia (29%) recognized p210Bcr-Abl when used in immunoprecipitation followed by immunoblotting experiments. In all 18 patients, plasma was able to recognize baculovirus-expressed Abl protein; in four patients, recognition of baculovirus-expressed Bcr protein was also demonstrated. These observations suggest that a humoral immune response to p210Bcr-Abl is discernible in both Ph-positive and -negative leukemias and in healthy individuals, and is most likely due to autoantibodies which recognize normal Abl and, to a lesser extent, normal Bcr proteins.
Author List
Talpaz M, Qiu X, Cheng K, Cortes JE, Kantarjian H, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Autoantibodies
Female
Fusion Proteins, bcr-abl
Humans
K562 Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Male
Middle Aged
Oncogene Proteins
Philadelphia Chromosome
Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-abl
Proto-Oncogene Proteins c-bcr